Proteoglycan-targeted antibodies as markers on non-Hodgkin lymphoma xenografts
Summary A family of mono- and polyclonal antibodies raised against proteoglycans or their “subcomponents” served as novel markers to characterize the phenotypes of three non-Hodgkin lymphoma xenograft lines (HT 58 lymphoblastic, HT 117 centroblastic, HT 130 centrocytic) together with normal, human p...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1990 |
|---|
| Umfang: |
6 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: Cancer immunology immunotherapy - 1976, 32(1990) vom: Feb., Seite 137-142 |
| Übergeordnetes Werk: |
volume:32 ; year:1990 ; month:02 ; pages:137-142 ; extent:6 |
| Links: |
|---|
| Katalog-ID: |
NLEJ202851133 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ202851133 | ||
| 003 | DE-627 | ||
| 005 | 20210706112116.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070528s1990 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ202851133 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Proteoglycan-targeted antibodies as markers on non-Hodgkin lymphoma xenografts |
| 264 | 1 | |c 1990 | |
| 300 | |a 6 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Summary A family of mono- and polyclonal antibodies raised against proteoglycans or their “subcomponents” served as novel markers to characterize the phenotypes of three non-Hodgkin lymphoma xenograft lines (HT 58 lymphoblastic, HT 117 centroblastic, HT 130 centrocytic) together with normal, human peripheral blood B lymphocytes. These xenografted NHL lines, maintained by serial transplantations on artificially immunosuppressed mice, expressed very similar B-cell-related antigens and differences on the cell surface (HT 58 > HT 117 > HT 130 > B cells) when they were exposed to monoclonal antibodies (mAb) to cartilage proteoglycans. Anti-proteoglycan antibodies used in this study recognize complex epitopes of core protein segment associated with carbohydrate, shared by human cartilage proteoglycans and certain lymphoma cells. The binding of these antibodies was independent of cell-cycle phase. The results suggest that the anti-proteoglycan mAbs could be used as new phenotypic markers to individualize non-Hodgkin lymphomas. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Kopper, Laszlo |4 oth | |
| 700 | 1 | |a Bankfalvi, Agnes |4 oth | |
| 700 | 1 | |a Mihalik, Rudolf |4 oth | |
| 700 | 1 | |a Glant, Tibor T. |4 oth | |
| 700 | 1 | |a Timar, Jozsef |4 oth | |
| 773 | 0 | 8 | |i in |t Cancer immunology immunotherapy |d 1976 |g 32(1990) vom: Feb., Seite 137-142 |w (DE-627)NLEJ188986774 |w (DE-600)1458489-x |x 1432-0851 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:1990 |g month:02 |g pages:137-142 |g extent:6 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/BF01754211 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 1990 |c 2 |h 137-142 |g 6 | ||
| matchkey_str |
article:14320851:1990----::rtolcnagtdnioissakronnogi |
|---|---|
| hierarchy_sort_str |
1990 |
| publishDate |
1990 |
| allfields |
(DE-627)NLEJ202851133 DE-627 ger DE-627 rakwb eng Proteoglycan-targeted antibodies as markers on non-Hodgkin lymphoma xenografts 1990 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary A family of mono- and polyclonal antibodies raised against proteoglycans or their “subcomponents” served as novel markers to characterize the phenotypes of three non-Hodgkin lymphoma xenograft lines (HT 58 lymphoblastic, HT 117 centroblastic, HT 130 centrocytic) together with normal, human peripheral blood B lymphocytes. These xenografted NHL lines, maintained by serial transplantations on artificially immunosuppressed mice, expressed very similar B-cell-related antigens and differences on the cell surface (HT 58 > HT 117 > HT 130 > B cells) when they were exposed to monoclonal antibodies (mAb) to cartilage proteoglycans. Anti-proteoglycan antibodies used in this study recognize complex epitopes of core protein segment associated with carbohydrate, shared by human cartilage proteoglycans and certain lymphoma cells. The binding of these antibodies was independent of cell-cycle phase. The results suggest that the anti-proteoglycan mAbs could be used as new phenotypic markers to individualize non-Hodgkin lymphomas. Springer Online Journal Archives 1860-2002 Kopper, Laszlo oth Bankfalvi, Agnes oth Mihalik, Rudolf oth Glant, Tibor T. oth Timar, Jozsef oth in Cancer immunology immunotherapy 1976 32(1990) vom: Feb., Seite 137-142 (DE-627)NLEJ188986774 (DE-600)1458489-x 1432-0851 nnns volume:32 year:1990 month:02 pages:137-142 extent:6 http://dx.doi.org/10.1007/BF01754211 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 32 1990 2 137-142 6 |
| spelling |
(DE-627)NLEJ202851133 DE-627 ger DE-627 rakwb eng Proteoglycan-targeted antibodies as markers on non-Hodgkin lymphoma xenografts 1990 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary A family of mono- and polyclonal antibodies raised against proteoglycans or their “subcomponents” served as novel markers to characterize the phenotypes of three non-Hodgkin lymphoma xenograft lines (HT 58 lymphoblastic, HT 117 centroblastic, HT 130 centrocytic) together with normal, human peripheral blood B lymphocytes. These xenografted NHL lines, maintained by serial transplantations on artificially immunosuppressed mice, expressed very similar B-cell-related antigens and differences on the cell surface (HT 58 > HT 117 > HT 130 > B cells) when they were exposed to monoclonal antibodies (mAb) to cartilage proteoglycans. Anti-proteoglycan antibodies used in this study recognize complex epitopes of core protein segment associated with carbohydrate, shared by human cartilage proteoglycans and certain lymphoma cells. The binding of these antibodies was independent of cell-cycle phase. The results suggest that the anti-proteoglycan mAbs could be used as new phenotypic markers to individualize non-Hodgkin lymphomas. Springer Online Journal Archives 1860-2002 Kopper, Laszlo oth Bankfalvi, Agnes oth Mihalik, Rudolf oth Glant, Tibor T. oth Timar, Jozsef oth in Cancer immunology immunotherapy 1976 32(1990) vom: Feb., Seite 137-142 (DE-627)NLEJ188986774 (DE-600)1458489-x 1432-0851 nnns volume:32 year:1990 month:02 pages:137-142 extent:6 http://dx.doi.org/10.1007/BF01754211 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 32 1990 2 137-142 6 |
| allfields_unstemmed |
(DE-627)NLEJ202851133 DE-627 ger DE-627 rakwb eng Proteoglycan-targeted antibodies as markers on non-Hodgkin lymphoma xenografts 1990 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary A family of mono- and polyclonal antibodies raised against proteoglycans or their “subcomponents” served as novel markers to characterize the phenotypes of three non-Hodgkin lymphoma xenograft lines (HT 58 lymphoblastic, HT 117 centroblastic, HT 130 centrocytic) together with normal, human peripheral blood B lymphocytes. These xenografted NHL lines, maintained by serial transplantations on artificially immunosuppressed mice, expressed very similar B-cell-related antigens and differences on the cell surface (HT 58 > HT 117 > HT 130 > B cells) when they were exposed to monoclonal antibodies (mAb) to cartilage proteoglycans. Anti-proteoglycan antibodies used in this study recognize complex epitopes of core protein segment associated with carbohydrate, shared by human cartilage proteoglycans and certain lymphoma cells. The binding of these antibodies was independent of cell-cycle phase. The results suggest that the anti-proteoglycan mAbs could be used as new phenotypic markers to individualize non-Hodgkin lymphomas. Springer Online Journal Archives 1860-2002 Kopper, Laszlo oth Bankfalvi, Agnes oth Mihalik, Rudolf oth Glant, Tibor T. oth Timar, Jozsef oth in Cancer immunology immunotherapy 1976 32(1990) vom: Feb., Seite 137-142 (DE-627)NLEJ188986774 (DE-600)1458489-x 1432-0851 nnns volume:32 year:1990 month:02 pages:137-142 extent:6 http://dx.doi.org/10.1007/BF01754211 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 32 1990 2 137-142 6 |
| allfieldsGer |
(DE-627)NLEJ202851133 DE-627 ger DE-627 rakwb eng Proteoglycan-targeted antibodies as markers on non-Hodgkin lymphoma xenografts 1990 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary A family of mono- and polyclonal antibodies raised against proteoglycans or their “subcomponents” served as novel markers to characterize the phenotypes of three non-Hodgkin lymphoma xenograft lines (HT 58 lymphoblastic, HT 117 centroblastic, HT 130 centrocytic) together with normal, human peripheral blood B lymphocytes. These xenografted NHL lines, maintained by serial transplantations on artificially immunosuppressed mice, expressed very similar B-cell-related antigens and differences on the cell surface (HT 58 > HT 117 > HT 130 > B cells) when they were exposed to monoclonal antibodies (mAb) to cartilage proteoglycans. Anti-proteoglycan antibodies used in this study recognize complex epitopes of core protein segment associated with carbohydrate, shared by human cartilage proteoglycans and certain lymphoma cells. The binding of these antibodies was independent of cell-cycle phase. The results suggest that the anti-proteoglycan mAbs could be used as new phenotypic markers to individualize non-Hodgkin lymphomas. Springer Online Journal Archives 1860-2002 Kopper, Laszlo oth Bankfalvi, Agnes oth Mihalik, Rudolf oth Glant, Tibor T. oth Timar, Jozsef oth in Cancer immunology immunotherapy 1976 32(1990) vom: Feb., Seite 137-142 (DE-627)NLEJ188986774 (DE-600)1458489-x 1432-0851 nnns volume:32 year:1990 month:02 pages:137-142 extent:6 http://dx.doi.org/10.1007/BF01754211 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 32 1990 2 137-142 6 |
| allfieldsSound |
(DE-627)NLEJ202851133 DE-627 ger DE-627 rakwb eng Proteoglycan-targeted antibodies as markers on non-Hodgkin lymphoma xenografts 1990 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary A family of mono- and polyclonal antibodies raised against proteoglycans or their “subcomponents” served as novel markers to characterize the phenotypes of three non-Hodgkin lymphoma xenograft lines (HT 58 lymphoblastic, HT 117 centroblastic, HT 130 centrocytic) together with normal, human peripheral blood B lymphocytes. These xenografted NHL lines, maintained by serial transplantations on artificially immunosuppressed mice, expressed very similar B-cell-related antigens and differences on the cell surface (HT 58 > HT 117 > HT 130 > B cells) when they were exposed to monoclonal antibodies (mAb) to cartilage proteoglycans. Anti-proteoglycan antibodies used in this study recognize complex epitopes of core protein segment associated with carbohydrate, shared by human cartilage proteoglycans and certain lymphoma cells. The binding of these antibodies was independent of cell-cycle phase. The results suggest that the anti-proteoglycan mAbs could be used as new phenotypic markers to individualize non-Hodgkin lymphomas. Springer Online Journal Archives 1860-2002 Kopper, Laszlo oth Bankfalvi, Agnes oth Mihalik, Rudolf oth Glant, Tibor T. oth Timar, Jozsef oth in Cancer immunology immunotherapy 1976 32(1990) vom: Feb., Seite 137-142 (DE-627)NLEJ188986774 (DE-600)1458489-x 1432-0851 nnns volume:32 year:1990 month:02 pages:137-142 extent:6 http://dx.doi.org/10.1007/BF01754211 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 32 1990 2 137-142 6 |
| language |
English |
| source |
in Cancer immunology immunotherapy 32(1990) vom: Feb., Seite 137-142 volume:32 year:1990 month:02 pages:137-142 extent:6 |
| sourceStr |
in Cancer immunology immunotherapy 32(1990) vom: Feb., Seite 137-142 volume:32 year:1990 month:02 pages:137-142 extent:6 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Cancer immunology immunotherapy |
| authorswithroles_txt_mv |
Kopper, Laszlo @@oth@@ Bankfalvi, Agnes @@oth@@ Mihalik, Rudolf @@oth@@ Glant, Tibor T. @@oth@@ Timar, Jozsef @@oth@@ |
| publishDateDaySort_date |
1990-02-01T00:00:00Z |
| hierarchy_top_id |
NLEJ188986774 |
| id |
NLEJ202851133 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ202851133</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210706112116.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1990 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ202851133</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Proteoglycan-targeted antibodies as markers on non-Hodgkin lymphoma xenografts</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1990</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary A family of mono- and polyclonal antibodies raised against proteoglycans or their “subcomponents” served as novel markers to characterize the phenotypes of three non-Hodgkin lymphoma xenograft lines (HT 58 lymphoblastic, HT 117 centroblastic, HT 130 centrocytic) together with normal, human peripheral blood B lymphocytes. These xenografted NHL lines, maintained by serial transplantations on artificially immunosuppressed mice, expressed very similar B-cell-related antigens and differences on the cell surface (HT 58 > HT 117 > HT 130 > B cells) when they were exposed to monoclonal antibodies (mAb) to cartilage proteoglycans. Anti-proteoglycan antibodies used in this study recognize complex epitopes of core protein segment associated with carbohydrate, shared by human cartilage proteoglycans and certain lymphoma cells. The binding of these antibodies was independent of cell-cycle phase. The results suggest that the anti-proteoglycan mAbs could be used as new phenotypic markers to individualize non-Hodgkin lymphomas.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kopper, Laszlo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bankfalvi, Agnes</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mihalik, Rudolf</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Glant, Tibor T.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Timar, Jozsef</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Cancer immunology immunotherapy</subfield><subfield code="d">1976</subfield><subfield code="g">32(1990) vom: Feb., Seite 137-142</subfield><subfield code="w">(DE-627)NLEJ188986774</subfield><subfield code="w">(DE-600)1458489-x</subfield><subfield code="x">1432-0851</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:32</subfield><subfield code="g">year:1990</subfield><subfield code="g">month:02</subfield><subfield code="g">pages:137-142</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF01754211</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">32</subfield><subfield code="j">1990</subfield><subfield code="c">2</subfield><subfield code="h">137-142</subfield><subfield code="g">6</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ188986774 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1432-0851 |
| topic_title |
Proteoglycan-targeted antibodies as markers on non-Hodgkin lymphoma xenografts |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
l k lk a b ab r m rm t t g tt ttg j t jt |
| hierarchy_parent_title |
Cancer immunology immunotherapy |
| hierarchy_parent_id |
NLEJ188986774 |
| hierarchy_top_title |
Cancer immunology immunotherapy |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ188986774 (DE-600)1458489-x |
| title |
Proteoglycan-targeted antibodies as markers on non-Hodgkin lymphoma xenografts |
| spellingShingle |
Proteoglycan-targeted antibodies as markers on non-Hodgkin lymphoma xenografts |
| ctrlnum |
(DE-627)NLEJ202851133 |
| title_full |
Proteoglycan-targeted antibodies as markers on non-Hodgkin lymphoma xenografts |
| journal |
Cancer immunology immunotherapy |
| journalStr |
Cancer immunology immunotherapy |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1990 |
| contenttype_str_mv |
zzz |
| container_start_page |
137 |
| container_volume |
32 |
| physical |
6 |
| format_se |
Elektronische Aufsätze |
| title_sort |
proteoglycan-targeted antibodies as markers on non-hodgkin lymphoma xenografts |
| title_auth |
Proteoglycan-targeted antibodies as markers on non-Hodgkin lymphoma xenografts |
| abstract |
Summary A family of mono- and polyclonal antibodies raised against proteoglycans or their “subcomponents” served as novel markers to characterize the phenotypes of three non-Hodgkin lymphoma xenograft lines (HT 58 lymphoblastic, HT 117 centroblastic, HT 130 centrocytic) together with normal, human peripheral blood B lymphocytes. These xenografted NHL lines, maintained by serial transplantations on artificially immunosuppressed mice, expressed very similar B-cell-related antigens and differences on the cell surface (HT 58 > HT 117 > HT 130 > B cells) when they were exposed to monoclonal antibodies (mAb) to cartilage proteoglycans. Anti-proteoglycan antibodies used in this study recognize complex epitopes of core protein segment associated with carbohydrate, shared by human cartilage proteoglycans and certain lymphoma cells. The binding of these antibodies was independent of cell-cycle phase. The results suggest that the anti-proteoglycan mAbs could be used as new phenotypic markers to individualize non-Hodgkin lymphomas. |
| abstractGer |
Summary A family of mono- and polyclonal antibodies raised against proteoglycans or their “subcomponents” served as novel markers to characterize the phenotypes of three non-Hodgkin lymphoma xenograft lines (HT 58 lymphoblastic, HT 117 centroblastic, HT 130 centrocytic) together with normal, human peripheral blood B lymphocytes. These xenografted NHL lines, maintained by serial transplantations on artificially immunosuppressed mice, expressed very similar B-cell-related antigens and differences on the cell surface (HT 58 > HT 117 > HT 130 > B cells) when they were exposed to monoclonal antibodies (mAb) to cartilage proteoglycans. Anti-proteoglycan antibodies used in this study recognize complex epitopes of core protein segment associated with carbohydrate, shared by human cartilage proteoglycans and certain lymphoma cells. The binding of these antibodies was independent of cell-cycle phase. The results suggest that the anti-proteoglycan mAbs could be used as new phenotypic markers to individualize non-Hodgkin lymphomas. |
| abstract_unstemmed |
Summary A family of mono- and polyclonal antibodies raised against proteoglycans or their “subcomponents” served as novel markers to characterize the phenotypes of three non-Hodgkin lymphoma xenograft lines (HT 58 lymphoblastic, HT 117 centroblastic, HT 130 centrocytic) together with normal, human peripheral blood B lymphocytes. These xenografted NHL lines, maintained by serial transplantations on artificially immunosuppressed mice, expressed very similar B-cell-related antigens and differences on the cell surface (HT 58 > HT 117 > HT 130 > B cells) when they were exposed to monoclonal antibodies (mAb) to cartilage proteoglycans. Anti-proteoglycan antibodies used in this study recognize complex epitopes of core protein segment associated with carbohydrate, shared by human cartilage proteoglycans and certain lymphoma cells. The binding of these antibodies was independent of cell-cycle phase. The results suggest that the anti-proteoglycan mAbs could be used as new phenotypic markers to individualize non-Hodgkin lymphomas. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
Proteoglycan-targeted antibodies as markers on non-Hodgkin lymphoma xenografts |
| url |
http://dx.doi.org/10.1007/BF01754211 |
| remote_bool |
true |
| author2 |
Kopper, Laszlo Bankfalvi, Agnes Mihalik, Rudolf Glant, Tibor T. Timar, Jozsef |
| author2Str |
Kopper, Laszlo Bankfalvi, Agnes Mihalik, Rudolf Glant, Tibor T. Timar, Jozsef |
| ppnlink |
NLEJ188986774 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth |
| up_date |
2024-07-06T09:04:04.337Z |
| _version_ |
1803819831094411264 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ202851133</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210706112116.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1990 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ202851133</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Proteoglycan-targeted antibodies as markers on non-Hodgkin lymphoma xenografts</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1990</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary A family of mono- and polyclonal antibodies raised against proteoglycans or their “subcomponents” served as novel markers to characterize the phenotypes of three non-Hodgkin lymphoma xenograft lines (HT 58 lymphoblastic, HT 117 centroblastic, HT 130 centrocytic) together with normal, human peripheral blood B lymphocytes. These xenografted NHL lines, maintained by serial transplantations on artificially immunosuppressed mice, expressed very similar B-cell-related antigens and differences on the cell surface (HT 58 > HT 117 > HT 130 > B cells) when they were exposed to monoclonal antibodies (mAb) to cartilage proteoglycans. Anti-proteoglycan antibodies used in this study recognize complex epitopes of core protein segment associated with carbohydrate, shared by human cartilage proteoglycans and certain lymphoma cells. The binding of these antibodies was independent of cell-cycle phase. The results suggest that the anti-proteoglycan mAbs could be used as new phenotypic markers to individualize non-Hodgkin lymphomas.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kopper, Laszlo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bankfalvi, Agnes</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mihalik, Rudolf</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Glant, Tibor T.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Timar, Jozsef</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Cancer immunology immunotherapy</subfield><subfield code="d">1976</subfield><subfield code="g">32(1990) vom: Feb., Seite 137-142</subfield><subfield code="w">(DE-627)NLEJ188986774</subfield><subfield code="w">(DE-600)1458489-x</subfield><subfield code="x">1432-0851</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:32</subfield><subfield code="g">year:1990</subfield><subfield code="g">month:02</subfield><subfield code="g">pages:137-142</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF01754211</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">32</subfield><subfield code="j">1990</subfield><subfield code="c">2</subfield><subfield code="h">137-142</subfield><subfield code="g">6</subfield></datafield></record></collection>
|
| score |
7.399641 |